Phase 3 CLL Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled115 locationsNCT06846671
Recruiting
Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled52 locationsNCT05947851
Recruiting
Phase 3
Global Trial in APG2575 for Patients With CLL/SLL
CLL/SLL
Ascentage Pharma Group Inc.400 enrolled2 locationsNCT06104566
Not Yet Recruiting
Phase 3
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation
CancerChronic Lymphocytic Leukemia (CLL)Richter Transformation
Australasian Leukaemia and Lymphoma Group116 enrolled7 locationsACTRN12625000965404
Recruiting
Phase 3
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
CLL/SLL
Ascentage Pharma Group Inc.344 enrolled6 locationsNCT06319456
Recruiting
Phase 2Phase 3
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
CLL
Rigshospitalet, Denmark212 enrolled7 locationsNCT03868722
Completed
Phase 3
The research project is trying to find out if we can improve the results of best available chemotherapy for Chronic Lymphocytic Leukaemia (CLL) by the addition of a new drug called lenalidomide.
Chronic Lymphocytic Leukaemia (CLL)
Australasian Leukaemia and Lymphoma Group (ALLG)192 enrolled1 locationACTRN12610000060044